HUE037733T2 - Liofilizálási eljárások, készítmények, és készletek - Google Patents

Liofilizálási eljárások, készítmények, és készletek

Info

Publication number
HUE037733T2
HUE037733T2 HUE10833862A HUE10833862A HUE037733T2 HU E037733 T2 HUE037733 T2 HU E037733T2 HU E10833862 A HUE10833862 A HU E10833862A HU E10833862 A HUE10833862 A HU E10833862A HU E037733 T2 HUE037733 T2 HU E037733T2
Authority
HU
Hungary
Prior art keywords
kits
compositions
lyophilization methods
lyophilization
methods
Prior art date
Application number
HUE10833862A
Other languages
English (en)
Inventor
Jianxin Guo
Anthony Klos
Deborah Barnette
Original Assignee
Grifols Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44067198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE037733(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Therapeutics Inc filed Critical Grifols Therapeutics Inc
Publication of HUE037733T2 publication Critical patent/HUE037733T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Drying Of Solid Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE10833862A 2009-11-24 2010-11-23 Liofilizálási eljárások, készítmények, és készletek HUE037733T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26401409P 2009-11-24 2009-11-24

Publications (1)

Publication Number Publication Date
HUE037733T2 true HUE037733T2 (hu) 2018-09-28

Family

ID=44067198

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10833862A HUE037733T2 (hu) 2009-11-24 2010-11-23 Liofilizálási eljárások, készítmények, és készletek

Country Status (19)

Country Link
US (1) US8648177B2 (hu)
EP (1) EP2503995B1 (hu)
JP (2) JP5810091B2 (hu)
KR (1) KR101567901B1 (hu)
CN (1) CN102762196B (hu)
AU (1) AU2010324839B2 (hu)
BR (1) BR112012012460B1 (hu)
CA (1) CA2781120C (hu)
CL (1) CL2012001350A1 (hu)
ES (1) ES2648249T3 (hu)
HU (1) HUE037733T2 (hu)
IL (1) IL219827A (hu)
MX (1) MX2012005782A (hu)
NZ (1) NZ600271A (hu)
PL (1) PL2503995T3 (hu)
PT (1) PT2503995T (hu)
RU (1) RU2540480C2 (hu)
WO (1) WO2011066291A2 (hu)
ZA (1) ZA201203603B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599783A (en) 2009-11-03 2013-10-25 Grifols Therapeutics Inc Composition and use for alpha-1 proteinase inhibitor
JP5810091B2 (ja) 2009-11-24 2015-11-11 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 凍結乾燥方法、組成物、及びキット
WO2011140519A2 (en) 2010-05-07 2011-11-10 Medicus Biosciences, Llc In vivo gelling pharmaceutical pre-formulation
US11083821B2 (en) 2011-08-10 2021-08-10 C.P. Medical Corporation Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
US10111985B2 (en) 2011-08-10 2018-10-30 Medicus Biosciences, Llc Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
WO2013170195A1 (en) 2012-05-11 2013-11-14 Medicus Biosciences, Llc Biocompatible hydrogel treatments for retinal detachment
PL3421051T3 (pl) 2012-08-16 2020-10-05 Pfizer Inc. Sposoby glikokoniugacji i kompozycje
MX2015008944A (es) * 2013-01-15 2016-06-21 Teva Pharma Proceso de liofilizacion.
EP2968680B1 (en) 2013-03-14 2023-05-03 C.P. Medical Corporation Solid polyglycol-based biocompatible pre-formulation
US10004043B2 (en) 2013-06-18 2018-06-19 Lg Electronics Inc. Method for controlling electric power in wireless communication system supporting change in purpose of wireless resource and apparatus therefor
KR20160072266A (ko) 2013-11-07 2016-06-22 독토르. 아우구스트 볼프 게엠베하 운트 코. 카게 아르쯔네이미텔 안정하게 저장될 수 있는 동결건조 트리펩티드 제제
KR102021605B1 (ko) * 2015-02-13 2019-09-16 주식회사 씨젠 다중타겟 핵산서열 증폭반응용 조성물의 동결건조 방법
CN104856965B (zh) * 2015-05-29 2018-07-20 湖南科伦制药有限公司 一种注射用胸腺肽的冻干方法
EP3348271A4 (en) 2015-09-07 2018-08-22 Mochida Pharmaceutical Co., Ltd. Freeze-dried alginic acid preparation
TW201715185A (zh) * 2015-10-29 2017-05-01 Tai Yiaeh Enterprise Co Ltd 冷凍過程的即時檢測方法
CN107677528A (zh) * 2017-09-20 2018-02-09 上海贞元诊断用品科技有限公司 一种肝素抗凝检测试剂的校准品及质控品及其制备方法
CN107467013A (zh) * 2017-09-20 2017-12-15 上海贞元诊断用品科技有限公司 一种可长期保存的质控品通用血浆基质制备方法
CA3078625C (en) 2017-10-09 2023-01-17 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
CA3130668A1 (en) 2019-03-14 2020-12-03 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
WO2024150915A1 (ko) * 2023-01-11 2024-07-18 주식회사 풀바이오스 미세먼지로 인한 피부 손상 보호 및 탈모 방지용 조성물 및 그 제조방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087415A (en) * 1976-06-09 1978-05-02 William L. Wilson Antithrombin III
JPS597693B2 (ja) * 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
US4337242A (en) 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
US5218091A (en) 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
DE3581328D1 (de) 1984-06-19 1991-02-21 Transgene Sa Derivate des menschlichen alpha-1-antitrypins und verfahren zu deren herstellung.
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE3901917A1 (de) 1989-01-24 1990-07-26 Behringwerke Ag Mutanten von humanem antithrombin iii
GB8913183D0 (en) 1989-06-08 1989-07-26 Central Blood Lab Authority Chemical products
US5079336A (en) 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5032405A (en) 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
JP3479539B2 (ja) 1992-04-10 2003-12-15 エーザイ株式会社 ヒトアンチトロンビンｉｉｉ変異体
US5561115A (en) 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
AT405905B (de) * 1997-03-25 1999-12-27 Immuno Ag Neue verwendung von antithrombin iii
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
EP1079791A4 (en) 1998-05-12 2003-09-03 Susan C Bock HUMAN ANTITHROMBINS III AND RELATED METHODS
EP1154796B1 (en) 1999-02-22 2007-06-20 University of Connecticut Novel albumin-free factor viii formulations
US20040157911A1 (en) 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
WO2002002793A1 (fr) 2000-07-05 2002-01-10 Japan As Represented By Secretary Of Osaka University Processus de production de glycoproteine
US6432658B1 (en) * 2000-09-13 2002-08-13 Affinity Biologicals, Inc. Method for measuring antithrombin activity
WO2003035051A2 (en) 2001-10-19 2003-05-01 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
WO2003086451A1 (en) 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
MXPA04010560A (es) 2002-04-25 2005-08-15 Scripps Research Inst Tratamiento y prevencion de condiciones pulmonares.
ATE391730T1 (de) 2003-09-22 2008-04-15 Kamada Ltd Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
CA2545855A1 (en) 2003-11-14 2005-06-02 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
EP1720519A1 (en) 2004-03-04 2006-11-15 Wyeth Lyophilization method to improve excipient crystallization
BRPI0618893A2 (pt) * 2005-11-22 2011-09-13 Wyeth Corp formulações de proteìna de fusão de imunoglobulina
AU2007213344B2 (en) 2006-02-09 2012-11-15 Kamada Ltd. Pulmonary delivery of alpha-I proteinase inhibitor
CN101523143A (zh) * 2006-10-03 2009-09-02 惠氏公司 冻干方法和装置
JP5810091B2 (ja) 2009-11-24 2015-11-11 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 凍結乾燥方法、組成物、及びキット

Also Published As

Publication number Publication date
PT2503995T (pt) 2017-11-23
EP2503995A2 (en) 2012-10-03
WO2011066291A2 (en) 2011-06-03
RU2540480C2 (ru) 2015-02-10
EP2503995A4 (en) 2014-05-21
KR20120102715A (ko) 2012-09-18
BR112012012460B1 (pt) 2020-06-23
KR101567901B1 (ko) 2015-11-10
MX2012005782A (es) 2012-08-03
IL219827A0 (en) 2012-07-31
CN102762196A (zh) 2012-10-31
AU2010324839A1 (en) 2012-06-14
JP5810091B2 (ja) 2015-11-11
BR112012012460A8 (pt) 2018-07-03
JP2015155455A (ja) 2015-08-27
CL2012001350A1 (es) 2012-09-28
US20130040890A1 (en) 2013-02-14
CA2781120C (en) 2015-01-27
ZA201203603B (en) 2016-01-27
WO2011066291A4 (en) 2011-12-22
AU2010324839B2 (en) 2015-02-19
JP2013512194A (ja) 2013-04-11
NZ600271A (en) 2013-09-27
PL2503995T3 (pl) 2018-01-31
EP2503995B1 (en) 2017-11-01
US8648177B2 (en) 2014-02-11
CN102762196B (zh) 2014-05-14
ES2648249T3 (es) 2017-12-29
IL219827A (en) 2016-12-29
RU2012126125A (ru) 2013-12-27
CA2781120A1 (en) 2011-06-03
WO2011066291A3 (en) 2011-10-06
BR112012012460A2 (pt) 2017-10-10

Similar Documents

Publication Publication Date Title
ZA201203603B (en) Lyophilization methods, compositions, and kits
IL210153A0 (en) Nutrigenomics methods and compositions
IL212822A0 (en) Anti-cxcr1 compositions and methods
GB0819530D0 (en) Methods and compositions
IL210559A0 (en) Novel compositions and methods
IL210588A0 (en) Novel compositions and methods
GB0903299D0 (en) Composition and methods
GB0817585D0 (en) Novel compositions and methods
EP2438173A4 (en) BIOMATERIALS, COMPOSITIONS AND METHODS
HK1149770A1 (en) Compositions, methods and kits
GB0901494D0 (en) Compositions and Methods
HRP20150021T1 (en) Phenanthrenone compounds, compositions and methods
GB0811250D0 (en) Methods and compositions
GB0912287D0 (en) Cells, compositions and methods
GB0913162D0 (en) Compositions and kits
GB0901234D0 (en) Composition,method and use
GB0901227D0 (en) Composition,method and use
GB0901293D0 (en) Composition, method and use
GB0818399D0 (en) Methods and compositions
GB0816534D0 (en) Compositions and methods
GB0811152D0 (en) Methods and compositions
GB0803464D0 (en) Methods and compositions